A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

Conclusions Combination trastuzumab, lapatinib, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with advanced malignancy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research